solifenacin accord 10 mg apvalkotās tabletes
accord healthcare b.v., netherlands - solifencīna sukcināts - apvalkotā tablete - 10 mg
solifenacin accord 5 mg apvalkotās tabletes
accord healthcare b.v., netherlands - solifencīna sukcināts - apvalkotā tablete - 5 mg
gribero 75 mg cietās kapsulas
sandoz d.d., slovenia - dabigatrāna eteksilāts - kapsula, cietā - 75 mg
gribero 150 mg cietās kapsulas
sandoz d.d., slovenia - dabigatrāna eteksilāts - kapsula, cietā - 150 mg
cyclophosphamide accord 500 mg pulveris injekciju/infūziju šķīduma pagatavošanai
accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 500 mg
cyclophosphamide accord 1000 mg pulveris injekciju/infūziju šķīduma pagatavošanai
accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg
etoricoxib zentiva 60 mg apvalkotās tabletes
zentiva, k.s., czech republic - etorikoksibs - apvalkotā tablete - 60 mg
rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiskie līdzekļi - venozās trombembolijas (vte) profilakse pieaugušiem pacientiem, kuriem tiek veikta gēnu vai ceļa locītavas locītavas operācija. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 haemodynamically nestabila pe pacientiem). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 un 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
bozilos 14 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - teriflunomīds - apvalkotā tablete - 14 mg
etoricoxib teva 90 mg apvalkotās tabletes
teva b.v., netherlands - etorikoksibs - apvalkotā tablete - 90 mg